Welcome to our dedicated page for Edesa Biotech SEC filings (Ticker: EDSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edesa Biotech, Inc. (Nasdaq: EDSA) SEC filings page compiles the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer focused on immuno-inflammatory diseases, Edesa uses its SEC reports to provide detail on clinical programs, funding agreements and capital markets activity related to its Medical Dermatology and Respiratory pipelines.
Investors can review current reports on Form 8-K that discuss material events such as positive Phase 3 results for paridiprubart (EB05) in Acute Respiratory Distress Syndrome (ARDS), amendments to a multi-year contribution agreement with the Government of Canada’s Strategic Innovation Fund, and updates to at-the-market equity offering programs. Other 8-K filings reference earnings releases for fiscal periods, giving context on operating expenses, research and development spending, and cash resources supporting programs like EB06 for vitiligo and EB01 for Allergic Contact Dermatitis.
Through its shelf registration statements and prospectus supplements, Edesa documents how it raises capital via at-the-market offerings and private placements of preferred and common shares. These filings outline the structure and size of offerings, use of proceeds for advancing EB06 into Phase 2 studies, and the terms under which additional common shares may be issued. Contribution agreements and amendments filed or referenced in periodic reports describe partially repayable government funding for EB05 clinical trials, regulatory submissions and non-clinical safety studies.
On Stock Titan, users can access Edesa’s SEC filings as they are made available from EDGAR and benefit from AI-powered summaries that highlight the key points in lengthy documents such as annual reports (Form 10-K), quarterly reports (Form 10-Q) and material 8-Ks. These tools help clarify disclosures on clinical milestones, financial obligations, government funding arrangements and equity issuance, and can also surface insider and governance-related filings such as Forms 3, 4 and 5 when they are filed. This page is a resource for analyzing how Edesa reports its progress, risks and capital structure in connection with its dermatology and respiratory drug candidates.
EDESA BIOTECH, INC. reports that Perceptive Life Sciences Master Fund, Ltd. directly holds 563,239 Common Shares, equal to 6.7% of the class based on 8,348,161 outstanding Common Shares as of February 12, 2026.
The Schedule 13G lists the Reporting Persons as Perceptive Advisors LLC, Joseph Edelman and the Master Fund; each is reported with shared voting and shared dispositive power over the 563,239 shares.
Edesa Biotech, Inc. President Michael J. Brooks purchased 2,000 common shares in an open-market trade at $1.57 per share on February 26, 2026. Following this transaction, he directly owns 226,870 common shares, indicating a relatively small, incremental increase in his personal stake.
Edesa Biotech, Inc. Chief Executive Officer Pardeep Nijhawan reported an open-market purchase of 1,000 Common Shares on March 10, 2026 at an average price of $6.5989 per share. Following this transaction, his direct holdings increased to 628,813 Common Shares.
He also reports indirect ownership positions, including 402,702 Common Shares held by Pardeep Nijhawan Medicine Professional Corporation and additional blocks held by The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc. He disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
Edesa Biotech CEO-associated entity buys additional shares. On March 5, 2026, Pardeep Nijhawan Medicine Professional Corporation, an entity wholly owned by Edesa Biotech CEO and 10% owner Pardeep Nijhawan, purchased 10,000 common shares of Edesa Biotech at $3.90 per share in an open-market transaction, reported as indirect ownership.
Following this purchase, that corporation held 402,702 common shares. Nijhawan also reported 627,813 common shares held directly, plus additional indirect holdings through The New Nijhawan Family Trust 2015 and several wholly owned entities, while disclaiming beneficial ownership beyond his pecuniary interest in those indirect positions.
Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an indirect open-market purchase of Common Shares. On March 4, 2026, Pardeep Nijhawan Medicine Professional Corporation, an entity wholly owned by him, bought 10,000 Common Shares at a price of $4.2560 per share. Following this transaction, that entity was reported to hold 392,702 Common Shares indirectly.
As of the same date, Nijhawan also reported 627,813 Common Shares held directly. Indirect holdings were additionally reported as 32,609 Common Shares held by The New Nijhawan Family Trust 2015, 32,013 Common Shares held by The Digestive Health Clinic Inc., and 53,104 Common Shares held by 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.
Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an indirect open-market purchase of 10,000 common shares on March 3, 2026 at a price per share of 3.63, through Pardeep Nijhawan Medicine Professional Corporation.
The filing also reports Nijhawan’s direct and additional indirect holdings in common shares, including positions held via The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.
Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported open-market purchases of company common shares. On March 2, 2026, he bought 2,000 common shares directly at $2.00 per share and an additional 1,000 common shares indirectly at $2.2796 per share through Pardeep Nijhawan Medicine Professional Corporation.
Following these transactions, direct holdings stood at 627,813 common shares. Indirectly, entities associated with him held 372,702 common shares at Pardeep Nijhawan Medicine Professional Corporation, 32,609 common shares at The New Nijhawan Family Trust 2015, 32,013 common shares at The Digestive Health Clinic Inc., and 53,104 common shares at 1968160 Ontario Inc. The report notes that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
Edesa Biotech, Inc. reported that Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. and Steven A. Cohen beneficially own 600,000 Common Shares, representing 7.2% of the class as of March 2, 2026.
The filing states the reported shares carry shared voting power and shared dispositive power of 600,000, and that Point72 Associates has the right to receive dividends or sale proceeds for more than 5% of outstanding Common Shares.
Velan Capital and affiliated entities have amended their Schedule 13D for Edesa Biotech, Inc., updating their reported ownership and capital structure details. The group now reports beneficial ownership of 834,700 common shares, or approximately 9.99% of Edesa’s outstanding shares, through various Velan funds and management entities. This includes 569,075 shares held by Velan Master, 250,000 shares held by Velan Opportunity II, and 15,625 shares held by Velan Horizon, some of which are issuable upon conversion of Preferred Shares subject to an ownership cap. Without this ownership limitation on the Preferred Shares, the reporting persons state they would collectively beneficially own 3,785,833 shares, or about 33.5% of the company’s common stock. The amendment also notes that previously issued warrants have expired worthless as of December 23, 2025.
Edesa Biotech’s major shareholder group led by Dr. Pardeep Nijhawan filed Amendment No. 9 to update their Schedule 13D. Dr. Nijhawan may be deemed to beneficially own 2,040,785 common shares, representing approximately 19.99% of Edesa’s outstanding common shares on a converted basis.
The filing details multiple restricted stock unit grants to Dr. Nijhawan in 2025 and early 2026, many issued in lieu of partial salary and bonus, as well as a larger 263,200-unit grant vesting over 12 and 36 months. On February 26, 2026, he bought 20,571 common shares at a weighted average price of $1.5789, and his professional corporation acquired 30,000 shares at a weighted average price of $2.2232, both using investment capital. The filing also describes a 19.99% beneficial ownership blocker on Series B-1 Preferred Shares.